Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 29;76(3):e1157–e1165. doi: 10.1093/cid/ciac692

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)

PMC Copyright notice

Figure 3. — Forest plot demonstrating the DOOR probabilities for the DOOR, DOOR prioritized for efficacy and safety, and the DOOR components (treatment failure, infectious complications, serious adverse events, and death) for each clinical trial (A. ZEUS; B. APEKS-cUTI; C. DORI-05). Abbreviations: CI, confidence interval; DOR, doripenem; DOOR, desirability of outcome ranking; FDC, cefiderocol; FOS, fosfomycin; IMP, imipenem-cilastatin; LVX, levofloxacin; SAE, serious adverse events; TZP, piperacillin/tazobactam.